Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 141

Results For "IND"

6288 News Found

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
News | September 11, 2025

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions


Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Digitisation | September 11, 2025

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines


Novo Nordisk to cut 9,000 jobs globally
News | September 11, 2025

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients


FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US
Drug Approval | September 10, 2025

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection


Schneider Electric and Apollo Hospitals collaborate for energy-efficient healthcare solutions
Sustainability | September 10, 2025

Schneider Electric and Apollo Hospitals collaborate for energy-efficient healthcare solutions

Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025


Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad
Healthcare | September 10, 2025

Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad

New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production


Novartis to acquire Tourmaline Bio for $1.4 billion
News | September 10, 2025

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease


MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
News | September 09, 2025

MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval